AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34686180 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise and functional rehabilitation program (1 month duration)
Number of subjects: 50
Study 34686180 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice care and normal health education program at discharge
Number of subjects: 50
Study 34686180 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise and functional rehabilitation program
Number of subjects: 50
Study 34686309 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 8 cm H2O and tidal volume settings
Number of subjects: 43
Study 34686309 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H2O and tidal volume settings
Number of subjects: 43
Study 34686340 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting TREM2 on tumor-associated macrophages
Number of subjects: 0
Study 34686372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum albumin (MAlb) level <36.1 g/L
Number of subjects: 3065
Study 34686372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum albumin (MAlb) level >36.1 g/L
Number of subjects: 3065
Study 34686372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum albumin (MAlb) levels
Number of subjects: 3065
Study 34686555 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA) followed by standard care
Number of subjects: 120
Study 34686555 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of supervised progressive resistance training (PRT) followed by 12 weeks of optional unsupervised PRT
Number of subjects: 120
Study 34686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil phagocytic activity
Number of subjects: 245
Study 34686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature granulocyte (IG) count
Number of subjects: 245
Study 34686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cell-free DNA (cfDNA) levels
Number of subjects: 245
Study 34686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily screening for sepsis using the 2007 American Burn Association diagnostic criteria
Number of subjects: 245
Study 34686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores
Number of subjects: 245
Study 34686642 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD subjects (n = 107; 22%)
Number of subjects: 482
Study 34686642 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD comorbidity
Number of subjects: 482
Study 34686642 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 482
Study 34686642 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD comorbidity after 6 weeks of antidepressant use
Number of subjects: 482
Study 34686642 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse, subthreshold hypomania, DMX
Number of subjects: 482
Study 34686832 — intervention group
Group type: EXPERIMENTAL
Intervention: ROP stage ≤3 without intervention
Number of subjects: 506
Study 34686832 — intervention group
Group type: COMPARATOR
Intervention: Children without ROP
Number of subjects: 506
Study 34686832 — intervention group
Group type: EXPERIMENTAL
Intervention: ROP with intervention
Number of subjects: 506
Study 34686934 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 19324
Study 34686934 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative MRI)
Number of subjects: 19324
Study 34687040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 0
Study 34687040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab 175-500 mg
Number of subjects: 0
Study 34687334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) as a first-line imaging technique
Number of subjects: 177
Study 34687334 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR) as a first-line imaging technique (historical control)
Number of subjects: 177
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone ownership
Number of subjects: 157
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet access via smartphone
Number of subjects: 157
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to unlimited data
Number of subjects: 157
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent use of text messaging
Number of subjects: 157
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent use of email
Number of subjects: 157
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent use of health-oriented applications
Number of subjects: 157
Study 34687401 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth interventions effectiveness
Number of subjects: 157
Study 34687412 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures of subcutaneous adipose tissue in women with BCRL
Number of subjects: 0
Study 34687412 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 0
Study 34687548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (50-12.5 mg/kg q8h for those ≥6 months to 18 years old; 40-10 mg/kg q8h for those ≥3 to 6 months old)
Number of subjects: 0
Study 34687548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 0
Study 34687691 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric capnography measurements
Number of subjects: 143
Study 34687726 — intervention group
Group type: EXPERIMENTAL
Intervention: Senolytic treatment (specific details on dosage and duration not available)
Number of subjects: 0
Study 34687726 — intervention group
Group type: EXPERIMENTAL
Intervention: Senolytic trials (NCT04063124 and NCT04685590)
Number of subjects: 0
Study 34687939 — intervention group
Group type: EXPERIMENTAL
Intervention: First HSCT
Number of subjects: 46
Study 34687939 — intervention group
Group type: COMPARATOR
Intervention: Prior blinatumomab therapy
Number of subjects: 46
Study 34687939 — intervention group
Group type: COMPARATOR
Intervention: Prior inotuzumab therapy
Number of subjects: 46
Study 34687939 — intervention group
Group type: COMPARATOR
Intervention: ≥5 prior lines of therapy
Number of subjects: 46
Study 34687939 — intervention group
Group type: COMPARATOR
Intervention: ≥5% blasts (M2/M3 marrow) pre-CAR T cell therapy
Number of subjects: 46
Study 34687939 — intervention group
Group type: COMPARATOR
Intervention: Primary refractory disease
Number of subjects: 46
Study 34688250 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotinib 350 mg
Number of subjects: 81
Study 34688250 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotinib 250 mg and 300 mg
Number of subjects: 81
Study 34688250 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotinib (all doses)
Number of subjects: 81
Study 34688250 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotinib (350 mg)
Number of subjects: 81
Study 34688256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Gadoxetate-enhanced (DGE) liver MRI
Number of subjects: 0
Study 34688256 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) liver function test
Number of subjects: 0
Study 34688272 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial model of cancer-related fatigue (CRF)
Number of subjects: 200
Study 34688291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit Card Intervention (QCI) - includes a 'Quit Card' worth $300 for nicotine replacement therapy, a self-help booklet, and 6 months of telephone follow-up counseling.
Number of subjects: 0
Study 34688291 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) - includes a brochure for a local smoking cessation program.
Number of subjects: 0
Study 34688291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit Card Intervention (QCI)
Number of subjects: 0
Study 34688291 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 34688290 — intervention group
Group type: EXPERIMENTAL
Intervention: Itch Numeric Rating Scale (NRS)
Number of subjects: 3
Study 34688290 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Pain Numeric Rating Scale (NRS)
Number of subjects: 3
Study 34688290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Sleep Scale (ADSS)
Number of subjects: 3
Study 34688290 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds for interpreting meaningful change
Number of subjects: 3
Study 34688997 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing in Cohort 1
Number of subjects: 5
Study 34688997 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted capture sequencing in Cohort 2
Number of subjects: 5
Study 34689233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIs combined with regorafenib
Number of subjects: 84
Study 34689733 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-oriented practice training (one-week training session)
Number of subjects: 66
Study 34689733 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of professional experience
Number of subjects: 66
Study 34689733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses and peer workers' roles
Number of subjects: 66
Study 34689830 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered decision coaching intervention
Number of subjects: 20
Study 34690090 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 145
Study 34690269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative central graft thickness (CGT) >130 μm
Number of subjects: 108
Study 34690269 — intervention group
Group type: COMPARATOR
Intervention: Preoperative central graft thickness (CGT) ≤130 μm
Number of subjects: 108
Study 34690269 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative central graft thickness (CGT) >100 μm
Number of subjects: 108
Study 34690269 — intervention group
Group type: COMPARATOR
Intervention: Postoperative central graft thickness (CGT) ≤100 μm
Number of subjects: 108
Study 34690269 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin 6-month postoperative grafts
Number of subjects: 108
Study 34690269 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month postoperative CGT
Number of subjects: 108
Study 34690269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CGT
Number of subjects: 108
Study 34690269 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative DSAEK-CGT
Number of subjects: 108
Study 34690671 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 28
Study 34690671 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 28
Study 34690736 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling for 20-50 mins, three times a week for 6 months
Number of subjects: 60
Study 34690736 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretching
Number of subjects: 60
Study 34690824 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid Alcohol Use Disorder
Number of subjects: 0
Study 34690824 — intervention group
Group type: COMPARATOR
Intervention: Control group (without alcohol use disorder)
Number of subjects: 0
Study 34690831 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available
Number of subjects: 0
Study 34690831 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34690837 — intervention group
Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills for Young Adults (PEERS®-YA-K)
Number of subjects: 0
Study 34690837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 34691079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 0
Study 34691243 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with bendamustine
Number of subjects: 40
Study 34692392 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 117
Study 34692392 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 117
Study 34692392 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 117
Study 34692470 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields/TMZ combination
Number of subjects: 134
Study 34692470 — intervention group
Group type: COMPARATOR
Intervention: TMZ monotherapy
Number of subjects: 134
Study 34692757 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal nerve block
Number of subjects: 0
Study 34692757 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 34692764 — intervention group
Group type: EXPERIMENTAL
Intervention: Freehand Stereotactic Image-Guidance
Number of subjects: 0
Study 34692846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiles (IL-6, IFN-)
Number of subjects: 35
Study 34693027 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34693288 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg to 300 mg once daily with TMZ
Number of subjects: 38
Study 34693505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg/day, median treatment duration 18.5 days, range 1-1130 days)
Number of subjects: 252
Study 34693505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 252
Study 34693508 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy initiated before the age of 5 years
Number of subjects: 84
Study 34693508 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy initiated after the age of 5 years
Number of subjects: 84
Study 34693508 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy achieving > 95% clearance
Number of subjects: 84
Study 34693515 — intervention group
Group type: COMPARATOR
Intervention: DPP4i
Number of subjects: 129465
Study 34693515 — intervention group
Group type: COMPARATOR
Intervention: GLP-1RA
Number of subjects: 129465
Study 34693515 — intervention group
Group type: COMPARATOR
Intervention: SGLT2i
Number of subjects: 129465
Study 34693720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline test (1 mg/kg over 5 minutes)
Number of subjects: 24
Study 34693720 — intervention group
Group type: COMPARATOR
Intervention: Control group (age, sex, and body surface area-matched)
Number of subjects: 24
Study 34693725 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 0
Study 34693725 — intervention group
Group type: COMPARATOR
Intervention: Prednisone/Prednisolone
Number of subjects: 0
Study 34693912 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mean GHBT AUC increase by 1-ppm
Number of subjects: 0
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ARV)
Number of subjects: 70
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up of PLWH
Number of subjects: 70
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir exposure
Number of subjects: 70
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine exposure
Number of subjects: 70
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine exposure
Number of subjects: 70
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine exposure
Number of subjects: 70
Study 34693931 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 70
Study 34693935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Score (PAS) by study personnel
Number of subjects: 101
Study 34693935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Score (PAS) by triage nurse
Number of subjects: 101
Study 34693935 — intervention group
Group type: EXPERIMENTAL
Intervention: Average PAS score
Number of subjects: 101
Study 34693989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for OCD
Number of subjects: 46
Study 34693989 — intervention group
Group type: COMPARATOR
Intervention: Anxiety management (control group)
Number of subjects: 46
Study 34693994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive counseling by a health professional other than the physician
Number of subjects: 112159
Study 34693994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-free smoking cessation medications
Number of subjects: 112159
Study 34693994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored printed materials
Number of subjects: 112159
Study 34693994 — intervention group
Group type: COMPARATOR
Intervention: Biomedical risk feedback
Number of subjects: 112159
Study 34693994 — intervention group
Group type: COMPARATOR
Intervention: Training or incentives for primary care providers
Number of subjects: 112159
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-based interventions to change practice in outside-school hours childcare settings
Number of subjects: 4458
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff- and parent-based interventions
Number of subjects: 4458
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff- and child-based interventions
Number of subjects: 4458
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-only based intervention
Number of subjects: 4458
Study 34694005 — intervention group
Group type: COMPARATOR
Intervention: Physical activity interventions
Number of subjects: 4458
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Online physical activity interventions
Number of subjects: 4458
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component interventions with a specific physical activity goal
Number of subjects: 4458
Study 34694005 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions
Number of subjects: 4458
Study 34694234 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-powered clinical decision support system (CDSS) used during visits 1 and 2
Number of subjects: 17
Study 34694234 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no CDSS used)
Number of subjects: 17
Study 34694263 — intervention group
Group type: EXPERIMENTAL
Intervention: Alagille syndrome (ALGS)
Number of subjects: 215
Study 34694263 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1 antitrypsin deficiency (A1AT)
Number of subjects: 215
Study 34694263 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive familial intrahepatic cholestasis (PFIC)
Number of subjects: 215
Study 34694263 — intervention group
Group type: COMPARATOR
Intervention: Test norms
Number of subjects: 215
Study 34694279 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAN group (specialized program for screening and treating anal neoplasia)
Number of subjects: 3878
Study 34694279 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up group (including men who have sex with men)
Number of subjects: 3878
Study 34694279 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 3878
Study 34694279 — intervention group
Group type: COMPARATOR
Intervention: Men who have sex with men (not screened)
Number of subjects: 3878
Study 34694279 — intervention group
Group type: COMPARATOR
Intervention: Lack of immune restoration
Number of subjects: 3878
Study 34694279 — intervention group
Group type: COMPARATOR
Intervention: CDC category C
Number of subjects: 3878
Study 34694279 — intervention group
Group type: COMPARATOR
Intervention: Non-men who have sex with men
Number of subjects: 3878
Study 34694279 — intervention group
Group type: COMPARATOR
Intervention: Follow-up group including non-men who have sex with men
Number of subjects: 3878
Study 34694435 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hs-cTnT values exceeding the biological variation defined by MID
Number of subjects: 0
Study 34694435 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes within MID
Number of subjects: 0
Study 34694529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sasanlimab (intravenous at 1, 3, or 10 mg/kg every 3 weeks)
Number of subjects: 38
Study 34694529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sasanlimab (subcutaneous at 300 mg every 4 weeks)
Number of subjects: 38
Study 34694529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sasanlimab (both intravenous and subcutaneous)
Number of subjects: 38
Study 34694878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus an optimized background regimen
Number of subjects: 0
Study 34694878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 0
Study 34694909 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed™ Advanced Hybrid Closed-Loop System
Number of subjects: 0
Study 34694909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34694911 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Rotating Permanent Magnet Stimulator (TRPMS), 10 consecutive 40-minute treatment sessions.
Number of subjects: 10
Study 34695274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar damage (measured by lesion loads and volumes)
Number of subjects: 838
Study 34695300 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased time spent in rehabilitation (90 to 1288 minutes per week, 3 to 7 days per week, 2 weeks to 6 months duration)
Number of subjects: 1412
Study 34695300 — intervention group
Group type: COMPARATOR
Intervention: Control group (less time in rehabilitation)
Number of subjects: 1412
Study 34695377 — intervention group
Group type: EXPERIMENTAL
Intervention: Y90-radioembolisation followed by nivolumab
Number of subjects: 40
Study 34695449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (FOLE) 1 g/kg/d
Number of subjects: 262
Study 34695449 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil lipid emulsion (SOLE) ≤3 g/kg/d
Number of subjects: 262
Study 34695525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 1844
Study 34695525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 1844
Study 34695525 — intervention group
Group type: COMPARATOR
Intervention: PEGASUS-only group
Number of subjects: 1844
Study 34695525 — intervention group
Group type: COMPARATOR
Intervention: COMPASS-only group
Number of subjects: 1844